VIDEO: Investigational FGF-21 improves liver fat, glycemic control markers in MASH, diabetes

BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.
Loomba and colleagues conducted a two-part, randomized, placebo-controlled phase 2a trial to evaluate the effect of BOS-580 (Boston Pharmaceuticals) on glycemic control biomarkers and liver steatosis among individuals with phenotypic MASH, who have or are at risk for diabetes.
“Diabetics have an increased risk for fibrosis progression, and there

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart